LXEO News
Archived Headlines
- Gene therapy biotech Lexeo Therapeutics sets terms for $126 million IPO 10/30/23
- US IPO Week Ahead: Biotech Lexeo and construction firm Shimmick kick off November IPO market 10/27/23
- US IPO Weekly Recap: Holdover Adlai Nortye leads 4 IPO week as more small deals enter the pipeline 09/29/23
- Gene therapy biotech Lexeo Therapeutics files for a $100 million IPO 09/29/23
Renaissance Capital's November IPO Market Update
Eleven US IPOs raised a combined $708 million in November, well below the month's historical 10-year average (16 IPOs, $4.2B). Deal flow was led by three sizable issuers, and remaining activity came from smaller companies, all of which raised $33 million or less...read more
CAR T cancer biotech CARGO Therapeutics targets a $300 million IPO, as it seeks to overcome weak trading from recent biotech listings
Another large biotech IPO has joined the calendar, seeking to buck the trend of mostly negative returns from recent listings in the industry. CARGO Therapeutics (CRGX) launched on Monday, planning to raise $300 million in what would be the...read more
US IPO Weekly Recap: Biotech Lexeo stumbles after $100 million IPO
After ending October on shaky footing, the IPO market kicked off November with a fairly quiet week. Three new issuers began trading, two of...read more
Gene therapy biotech Lexeo Therapeutics prices IPO at $11, below the range
Lexeo Therapeutics, a Phase 1 biotech developing gene therapies for cardio and neuro diseases, raised $100 million by offering 9.1 million shares at $11, below the range of $13 to $15. The company offered 91 thousand more shares than anticipated. Lexeo...read more